Summary:
In patients with diabetic foot ulcers (DFUs), oral sitagliptin (100 mg daily) in combination with standard therapy significantly improved ulcer healing rates, reduced ulcer area, and increased CD34+ endothelial progenitor cells and SDF-1α levels compared to standard conventional therapy alone, though it was associated with no reported adverse effects.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with type 2 diabetes mellitus presenting with diabetic foot ulcers (DFUs). |
| Intervention | Oral sitagliptin 100 mg once daily added to standard conventional therapy for DFUs. |
| Comparison | Standard conventional therapy alone for diabetic foot ulcers. |
| Outcome | Sitagliptin significantly improved ulcer healing rates (p < 0.05), reduced ulcer area, elevated peripheral blood CD34+ EPCs, and increased SDF-1α levels. There was a trend toward shorter healing time (p = 0.071), with no significant differences in HbA1c or adverse events reported. |
Clinical Context
Diabetic foot ulcers arise from a convergence of neuropathy, ischaemia and impaired wound repair, with chronic hyperglycaemia blunting angiogenesis and the recruitment of reparative cells. Endothelial progenitor cells (EPCs), identified by CD34 positivity, home to injured tissue and support new vessel formation, a process orchestrated in part by stromal cell-derived factor-1α (SDF-1α). SDF-1α is itself a substrate of dipeptidyl peptidase-4 (DPP-4); inhibiting DPP-4 with sitagliptin therefore raises local SDF-1α, potentially mobilising more EPCs to the wound bed and enhancing healing independent of glucose lowering. This provides a clear biological rationale for repurposing a familiar oral antidiabetic agent as a wound-healing adjunct, and the trial tests whether that mechanistic promise translates into measurable clinical benefit.
Clinical Pearls
- Better ulcer healing: Adding sitagliptin to standard care significantly improved ulcer healing rates (p < 0.05) and reduced ulcer area compared with conventional therapy alone.
- Mechanistic biomarkers moved: Treatment raised peripheral blood CD34+ EPCs and SDF-1α levels, supporting the proposed DPP-4 / SDF-1α / EPC pathway as the mode of action.
- Healing time only a trend: The reduction in time to healing did not reach significance (p = 0.071), so the speed-of-healing benefit remains unconfirmed.
- Glucose-independent and well tolerated: There were no significant differences in HbA1c, suggesting benefit beyond glycaemic control, and no adverse effects were reported.
Practical Application
Sitagliptin 100 mg once daily is a widely used, generally well-tolerated DPP-4 inhibitor, and this study positions it as a low-risk add-on to standard diabetic foot ulcer care — debridement, offloading, infection control and glycaemic management — rather than a replacement for any of these. For patients with type 2 diabetes and a foot ulcer who require or already take an oral antidiabetic, selecting or adding sitagliptin could offer a plausible wound-healing co-benefit. However, the evidence rests on a single small trial with surrogate biomarker endpoints and only a non-significant trend toward faster healing, so it should not displace established management. Standard wound care and multidisciplinary foot services remain the priority.
Broader Evidence Context
The SDF-1α–DPP-4 relationship is well described, and DPP-4 inhibitors have been explored experimentally for tissue repair and vascular regeneration, lending mechanistic credibility to these clinical findings. Within diabetes care, DPP-4 inhibitors are valued for their tolerability and weight-neutral, low-hypoglycaemia profile, though large cardiovascular outcome trials of the class have shown broadly neutral cardiovascular effects. Demonstrating an EPC-mediated wound-healing signal would be a novel extension of their role. The results are broadly consistent with prior work suggesting that enhancing progenitor-cell mobilisation can aid healing, but they remain preliminary. As with other adjuncts in this field, confirmation in larger randomised trials is needed before practice or guidelines would change.
Study Limitations
- The trial was small and likely single-centre, limiting statistical power and precision.
- The reduction in healing time was only a non-significant trend (p = 0.071), tempering the efficacy claim.
- Key signals included surrogate biomarkers (CD34+ EPCs, SDF-1α) rather than solely hard clinical endpoints.
- Follow-up did not address ulcer recurrence, amputation or other long-term outcomes.
- Generalisability is uncertain, and the absence of reported adverse effects over a short period does not establish long-term safety in this setting.
Bottom Line
Adding sitagliptin to standard care significantly improved diabetic foot ulcer healing and raised CD34+ EPCs and SDF-1α, supporting a glucose-independent, angiogenic mechanism with no reported adverse effects. As a familiar, well-tolerated oral agent, it is an attractive potential adjunct, but the small sample, surrogate endpoints and only a trend toward faster healing mean it should complement, not replace, established foot-ulcer care pending larger confirmatory trials.
Source: Wei Gao, et al. “Sitagliptin, a DPP-4 Inhibitor, Effectively Promotes the Healing of Diabetic Foot Ulcer: A Randomized Controlled Trial.” Read article here.
